# NRG-GY019 (NCT04095364)

> Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04095364
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Low Grade Fallopian Tube Serous Adenocarcinoma; Ovarian Low Grade Serous Adenocarcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Stage II Fallopian Tube Cancer AJCC v8; Stage II Ovarian Cancer AJCC v8; Stage II Primary Peritoneal Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8
- Interventions: Biopsy Procedure; Biospecimen Collection; Carboplatin; Imaging Procedure; Letrozole; Paclitaxel
- Enrollment: 450
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on NRG-GY019 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 7
- Podcasts: 6
- Bluesky threads: 2
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nrg-gy019-nct04095364

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04095364", "email": "<work email>"}; the inbox owner confirms by the emailed link.